



Serial No. 09/995,277

IN THE CLAIMS:


Please cancel Claims 112, 114, 115, 117, 121, 143, 144 and 146, 150.

Please amend Claims 108, 113 and 141 to read as follows:

Claims 1-107 (cancelled).

(108.) (previously amended) A pharmaceutical composition comprising:

a compound having the formula



or salts thereof,

wherein

W^1 and W^2 are independently CO_2R^3 , $\text{C}(=\text{NH})\text{NH}(\text{OH})$, $\text{PO}(\text{OR}^3)_2$ or $\text{C}(=\text{O})\text{CF}_3$, and at least one of W^1 and W^2 is CO_2R^3 ;

each of R^1 and R^2 is a bond, CH_2 or $\text{C}_1\text{-C}_6$ alkylene;


each of Ar^1 and Ar^2 is independently a $\text{C}_5\text{-C}_{20}$ aryl;

L is a linker selected from the group consisting of a methoxy, $\text{C}_2\text{-C}_{20}$ alkoxy, and $\text{C}_6\text{-C}_{20}$ aryl;

and,


R^3 is hydrogen or $\text{C}_1\text{-C}_6$ alkyl.

109. (previously added) The composition of Claim 108, wherein said compound is of the formula:




Serial No. 09/995,277

110. (previously added) The composition of Claim 108, wherein said compound is of the formula:



111. (previously added) The composition of Claim 108, wherein said compound is of the formula:




Claim 112 (cancelled).

113. (previously amended) The composition of Claim 108, wherein L is $-\text{CH}_2\text{O}-$.


Claims 114, 115 (cancelled).

116. (previously added) The composition of Claim 108, wherein the compound is of the formula:



Claim 115-121 (cancelled).

122. (amended) A method for inhibiting Fc receptor binding of immunoglobulin in a patient comprising administering to such patient a pharmaceutically effective amount of a compound of the formula:



or salts thereof,

wherein

W¹ and W² are independently CO₂R³, C(=NH)NH(OH), PO(OR³)₂ or C(=O)CF₃, and each at least one of W¹ and W² is independently CO₂R³, C(=NH)NH(OH), PO(OR³)₂ or C(=O)CF₃;

each of R¹ and R² is a bond, CH₂ or C₁-C₆ alkylene;

each of Ar¹ and Ar² is independently a C₅-C₂₀ aryl or C₁-C₂₀ heteroaryl;

L is a linker selected from the group consisting of a methoxy, C₂-C₂₀ alkoxy, and C₆-C₂₀ aryl comprising from 1 to about 20 atoms; and,

R³ is hydrogen or C₁-C₆ alkyl.

123. (previously added) The method of Claim 122, wherein said Fc receptor is selected from the group consisting of FcαR, FcεR, FcγR and mixtures thereof.

124. (previously added) The method of Claim 122, wherein said Fc receptor is selected from the group consisting of FcγRIIa, FcγRIIb, FcγRIIc and mixtures thereof.

Serial No. 09/995,277

125. (previously added) The method of Claim 122, wherein said method reduces IgG-mediated tissue damage in said patient.

126. (previously added) The method of Claim 122, wherein said method reduces inflammation in said patient.

127. (previously added) The method of Claim 122, wherein said method is used to treat an autoimmune disease.

128. (previously added) The method of Claim 122, wherein said method is used to treat a disease where aggregates of antibodies are produced or where immune complexes are produced by contact of antibody with intrinsic or extrinsic antigen.

129. (previously added) The method of Claim 128, wherein said disease is selected from the group consisting of immune complex diseases, autoimmune diseases, infectious diseases and vasculitides.

130. (previously added) The method of Claim 129, wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, immune thrombocytopenia, neutropenia, and hemolytic anemias.

131. (previously added) The method of Claim 129, wherein said vasculitides is selected from the group consisting of polyarteritis nodosa, and systemic vasculitis.

chronic idiopathic
systemic inflammation
+ necrosis
in arteries
inflammation

B
8/03

Serial No. 09/995,277


132. (previously added) The method of Claim 122, wherein said method is used to treat xenograft rejection.

133. (previously added) The method of Claim 129, wherein said infectious disease is selected from the group consisting of Dengue virus-dengue hemorrhagic fever and measles virus infection.


134. (previously added) The method of Claim 122, wherein said method reduces IgE-mediated response in said patient.

Claim 135 (cancelled).


136. (previously added) The method of Claim 122, wherein said compound is of the formula:



137. (previously added) The method of Claim 122, wherein said compound is of the formula:



138. (previously added) The method of Claim 122, wherein said compound is of the formula:



139. (previously added) The method of Claim 138, wherein W^1 and W^2 are CO_2H .

140. (previously added) The method of Claim 138, wherein R^1 and R^2 are a bond.

9. Claim 141 (cancelled).

Cx 142. (currently amended) The method of Claim 122 ~~140~~, wherein L is $-\text{CH}_2\text{O}-$.

Claims 143, 144 (cancelled).

145. (previously added) The method of Claim 140, wherein the compound is of the formula:

